Abstract LB311: Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells

Jesse Green(Sana Biotechnology (United States)), Terry J. Fry(University of Colorado Anschutz Medical Campus), Jesus Moreno(Sana Biotechnology (United States)), Reuben F. Burch(Sana Biotechnology (United States)), Mike DeCosta(Sana Biotechnology (United States)), Aesha Vakil(Sana Biotechnology (United States)), Adam Charlton(Bangor University), Misha Shamashkin(Sana Biotechnology (United States)), Sanket Phadke(Sana Biotechnology (United States)), Hosein Kouros‐Mehr(University of California, San Francisco), Stephanie Riofrio(Sana Biotechnology (United States)), Sarah Miller(Sana Biotechnology (United States)), Ouwen Liang(Sana Biotechnology (United States)), Nicholas J. Mozdzierz(Sana Biotechnology (United States)), Matthew Scott-Skandera(Sana Biotechnology (United States)), Kutlu G. Elpek(Sana Biotechnology (United States)), Amey Gaikwad(Sana Biotechnology (United States)), Brian Granger(Sana Biotechnology (United States)), Andrew Tucker(Sana Biotechnology (United States)), Kaely Gallagher(Sana Biotechnology (United States)), Neal Van Hoeven(Sana Biotechnology (United States))
Cancer Research
April 14, 2023
Cited by 0


Related Papers